Prevalence of sarcopenia and its association with clinical outcomes in heart failure: An updated meta-analysis and systematic review

Ruzhao Chen, Jiachen Xu, Yuge Wang, Benyue Jiang, Xiao Xu, Yang Lan, Jiang Wang, Xiufang Lin, Ruzhao Chen, Jiachen Xu, Yuge Wang, Benyue Jiang, Xiao Xu, Yang Lan, Jiang Wang, Xiufang Lin

Abstract

Background: Sarcopenia is thought to be strongly associated with heart failure, but meta-analyses with sufficient samples are still lacking to accurately address its clinical situation.

Hypothesis: Sarcopenia has a high prevalence in patients with heart failure and is closely related to adverse clinical outcomes.

Methods: Relevant databases were systematically searched in October 2021 and updated in July 2022. The data with high heterogeneity were combined with random effects model.

Results: Twenty-one studies with 68,556 HF patients were included. The combined prevalence of sarcopenia in HF patients was 31%. Subgroup analysis found that the prevalence of sarcopenia in HF patients was 35% in Asia, 31% in Europe, 25% in the Americas, 31% in people aged ≥65 years, 25% in people with age <65 years, 28% in HF with reduced ejection fraction (HFrEF) patients and 18% in HF with preserved ejection fraction (HFpEF) patients. In addition, our analysis shows that sarcopenia in patients with HF is associated with an increased risk of poor prognosis, with a combined hazard ratio [HR] of 1.64 (95% confidence interval [CI] = 1.20-5.25), sarcopenia was also associated with poor outcomes in HFrEF patients with pooled HR of 2.77 (95% CI = 1.29-5.95). However, it was not associated with poor outcomes in HFpEF patients with pooled HR of 1.61 (95% CI = 0.82-3.16).

Conclusions: The prevalence of sarcopenia is high in HF patients, and patients with HF, particularly those with reduced ejection fraction, are at high risk of adverse outcomes from sarcopenia. Therefore, early identification and intervention for sarcopenia were beneficial for improving the prognosis of HF patients.

Keywords: heart failure; meta-analysis; sarcopenia; systematic review; updated.

Conflict of interest statement

The authors declare no conflict of interest.

© 2023 The Authors. Clinical Cardiology published by Wiley Periodicals, LLC.

Figures

Figure 1
Figure 1
The flowchart for study screening
Figure 2
Figure 2
Prevalence of sarcopenia in patients with heart failure
Figure 3
Figure 3
Subgroup analyses of clinical outcome

References

    1. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137‐1146.
    1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599‐3726.
    1. Cruz‐Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019;393(10191):2636‐2646.
    1. Wilson JR, Martin JL, Schwartz D, Ferraro N. Exercise intolerance in patients with chronic heart failure: role of impaired nutritive flow to skeletal muscle. Circulation. 1984;69(6):1079‐1087.
    1. Curcio F, Testa G, Liguori I, et al. Sarcopenia and heart failure. Nutrients. 2020;12(1):211.
    1. Peterson SJ, Braunschweig CA. Prevalence of sarcopenia and associated outcomes in the clinical setting. Nutr Clin Pract. 2016;31(1):40‐48.
    1. Gielen E, O'Neill TW, Pye SR, et al. Endocrine determinants of incident sarcopenia in middle‐aged and elderly European men. J Cachexia Sarcopenia Muscle. 2015;6(3):242‐252.
    1. Dodds RM, Granic A, Davies K, Kirkwood TBL, Jagger C, Sayer AA. Prevalence and incidence of sarcopenia in the very old: findings from the Newcastle 85+ study: prevalence and incidence of sarcopenia in the very old. J Cachexia Sarcopenia Muscle. 2017;8(2):229‐237.
    1. Yu R, Wong M, Leung J, Lee J, Auyeung TW, Woo J. Incidence, reversibility, risk factors and the protective effect of high body mass index against sarcopenia in community‐dwelling older Chinese adults. Geriat Gerontol Int. 2014;14(Suppl 1):15‐28.
    1. Chen X, Hou L, Zhang Y, Dong B. Analysis of the prevalence of sarcopenia and its risk factors in the elderly in the chengdu community. J Nutr Health Aging. 2021;25(5):600‐605.
    1. Zhang Y, Zhang J, Ni W, et al. Sarcopenia in heart failure: a systematic review and meta‐analysis. ESC Heart Failure. 2021;8(2):1007‐1017.
    1. Cruz‐Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16‐31.
    1. Chen LK, Woo J, Assantachai P, et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020;21(3):300‐307.
    1. Fuggle N, Shaw S, Dennison E, Cooper C. Sarcopenia. Best Pract Res Clin Rheumatol. 2017;31(2):218‐242.
    1. Bozkurt B, Coats AJ, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the heart failure society of america, heart failure association of the european society of cardiology, Japanese heart failure society and writing committee of the universal definition of heart failure. J Card Fail. 2021;27:387‐ 413.
    1. Qiao YS, Chai YH, Gong HJ, et al. The association between diabetes mellitus and risk of sarcopenia: accumulated evidences from observational studies. Front Endocrinol. 2021;12:782391.
    1. Dai M, Lin T, Yue J, Dai L. Signatures and clinical significance of amino acid flux in sarcopenia: a systematic review and Meta‐Analysis. Front Endocrinol. 2021;12:725518.
    1. Messier V, Rabasa‐Lhoret R, Barbat‐Artigas S, Elisha B, Karelis AD, Aubertin‐Leheudre M. Menopause and sarcopenia: a potential role for sex hormones. Maturitas. 2011;68(4):331‐336.
    1. Shimokata H, Shimada H, Satake S, et al. Chapter 2 epidemiology of sarcopenia. Geriat Gerontol Int. 2018;18(suppl 1):13‐22.
    1. Michelini LC, O'Leary DS, Raven PB, Nóbrega ACL. Neural control of circulation and exercise: a translational approach disclosing interactions between central command, arterial baroreflex, and muscle metaboreflex. Am J Physiol Heart Circ Physiol. 2015;309(3):H381‐H392.
    1. Ligthart‐Melis GC, Luiking YC, Kakourou A, Cederholm T, Maier AB, de van der Schueren MAE. Frailty, sarcopenia, and malnutrition frequently (co‐)occur in hospitalized older adults: a systematic review and meta‐analysis. J Am Med Dir Assoc. 2020;21(9):1216‐1228.
    1. Bekfani T, Pellicori P, Morris DA, et al. Sarcopenia in patients with heart failure with preserved ejection fraction: impact on muscle strength, exercise capacity and quality of life. Int J Cardiol. 2016;222:41‐46.
    1. Konishi M, Kagiyama N, Kamiya K, et al. Impact of sarcopenia on prognosis in patients with heart failure with reduced and preserved ejection fraction. European Journal of Preventive Cardiology. 2021;28(9):1022‐1029.
    1. Iannuzzi‐Sucich M, Prestwood KM, Kenny AM. Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. J Gerontol A Biol Sci Med Sci. 2002;57(12):M772‐M777.
    1. Faulkner JA, Larkin LM, Claflin DR, Brooks SV. Age‐related changes in the structure and function of skeletal muscles. Clin Exp Pharmacol Physiol. 2007;34(11):1091‐1096.
    1. Papadopoulou S. Sarcopenia: a contemporary health problem among older adult populations. Nutrients. 2020;12(5):1293.
    1. Lau EMC, Lynn HSH, Woo JW, Kwok TCY, Melton LJ III. Prevalence of and risk factors for sarcopenia in elderly Chinese men and women. J Gerontol A Biol Sci Med Sci. 2005;60(2):213‐216.
    1. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc. 2002;50(5):889‐896.
    1. Yang Y, Zhang Q, Chen J, et al. Prevalence of sarcopenia was higher in women than in men: a cross‐sectional study from a rural area in eastern China. Peer J. 2021;10:e13678.
    1. Xin C, Sun X, Lu L, Shan L. Prevalence of sarcopenia in older Chinese adults: a systematic review and meta‐analysis. BMJ Open. 2021;11(8):e041879.
    1. Delmonico MJ, Harris TB, Visser M, et al. Longitudinal study of muscle strength, quality, and adipose tissue infiltration. Am J Clin Nutr. 2009;90(6):1579‐1585.
    1. Bischoff‐Ferrari HA, Orav JE, Kanis JA, et al. Comparative performance of current definitions of sarcopenia against the prospective incidence of falls among community‐dwelling seniors age 65 and older. Osteoporos Int. 2015;26(12):2793‐2802.
    1. Fragala MS, Dam TTL, Barber V, et al. Strength and function response to clinical interventions of older women categorized by weakness and low lean mass using classifications from the foundation for the National Institute of Health sarcopenia project. J Gerontol Series A. 2015;70(2):202‐209.
    1. Attaway A, Bellar A, Dieye F, Wajda D, Welch N, Dasarathy S. Clinical impact of compound sarcopenia in hospitalized older adult patients with heart failure. J Am Geriatr Soc. 2021;69(7):1815‐1825.
    1. Collamati A, Marzetti E, Calvani R, et al. Sarcopenia in heart failure: mechanisms and therapeutic strategies. J Geriat Cardiol. 2016;13(7):615‐624.
    1. Liu CF, Tang WHW. Gut microbiota in sarcopenia and heart failure. J Cardiovasc Aging. 2022;2(3):35.
    1. Billingsley HE, Del Buono MG, Canada JM, et al. Sarcopenic obesity is associated with reduced cardiorespiratory fitness compared with nonsarcopenic obesity in patients with heart failure with reduced ejection fraction. Circ Heart Failure. 2022;15(10):e009518.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever